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COMMENTARYoverlapping with the Vitiligo Impact Pa-
tient scale. As both scales were tested on
geographically diverse populations, this
supports the validity of the approach.
Previously, it has been shown that
several items of the dermatology life
quality index and Skindex are subject to
bias according to cultural differences
(Nijsten et al., 2007), suggesting that
for vitiligo, a global consensus might
best determine the impact score that
should be employed in epidemiological
studies and in clinical trials. Validation
in an international multicenter study
would likely be required.
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TRPV4 in Serotonin-Mediated Itch
Lindsey M. Snyder1,2, Marissa S. Kuzirian1,2 and Sarah E. Ross1,2,3Previous studies have revealed that TRPV1 and TRPA1 function downstream of
many itch receptors,where theymediate inwardcurrent to trigger actionpotentials
in primary afferents. Although other TRP channels, such as TRPV4, are expressed in
primary afferents,whether or not they play an analogous role in itchwaspreviously
unknown. Now, Akiyama et al. provide evidence that TRPV4 is a key mediator of
serotonin-induced itch. This ﬁnding is important because it uncovers an
unanticipated role for TRPV4 in itch, thereby identifying a novel therapeutic target.
Journal of Investigative Dermatology (2016) 136, 7e9. doi:10.1016/j.jid.2015.11.010Clinical relevance of itch
Chronic itch, which is defined as itch
lasting more than 6 weeks, is a prevalent
problem that occurs in approximately
10% of the population (Mollanazaret al., 2015). Chronic itch conditions
negatively affect quality of life, and yet
there are no therapies that are both effi-
cacious and selective for itch. The lackof
effective treatment is partly attributable, Pittsburgh, Pennsylvania, USA; 2The Pittsburgh
tsburgh, Pennsylvania, USA; and 3Department of
ennsylvania, USA
ittsburgh, PA 15213, USA. E-mail: saross@pitt.eduto a poor understanding of the mecha-
nisms that underlie it. Although antihis-
tamines are frequently prescribed as a
treatment for itch, they are typically
ineffective because most types of
chronic itch are not histamine-mediated
(Mollanazar et al., 2015). Unfortunately,
although there are numerous mediators
that can cause itch, the factors that
are responsible in most circumstances
of chronic itch are largely unknown.
One candidate mediator is serotonin
(5-hydroxytryptamine, 5-HT). Human
psychophysical studies have shown that
the application of serotonin into the skin
causes itch (Weisshaar et al., 2004). In
rodents, serotonin is a key component of
mast cells, and it is a potent mediator of
itch. However, until recently, the mech-
anisms through which serotonin causes
itch have remained uncertain.
TRPS as downstream mediators of
itch (pruritogens)
Many pruritogens bind to metabotropic
receptors on primary sensory neurons;
however, these receptors must be
coupled to ionotropic channels via
intracellular signaling pathways to allow
sufficient current influx to generate ac-
tion potentials. Several groups have
shown that the cation channels TRPV1
and TRPA1 are coupled to different
pruritogen receptors and that they are
critical for different forms of itch trans-
mission (Ross, 2011). More specifically,
TRPV1 is required for histaminergic itch,
whereas TRPA1 is required for several
types of nonhistaminergic itch, such as
that induced by chloroquine, BAM8-22,
IL-31, endothelin-1, thymic stromal
lymphopoietin, and bile acids. Until
recently, whether serotonin receptors
were likewise coupled to TRPs remained
unknown.
TRPV4 is a keymediator
of serotonin-induced
itch, thereby identifying
a novel therapeutic
target.Mechanisms of serotonin-induced itch
Understanding serotonin-mediated itch
has been complicated by the fact that
there are numerous serotonin receptors
that are expressed on primary afferents,
as well as on immune mediators thatwww.jidonline.org 7
Figure 1. TRPV4 is a key mediator of serotonin-induced itch. Akiyama et al. (2016) provide evidence
that the serotonin receptor (5-HTR, blue) couples to TRPV4 (red) to mediate the activation of primary
sensory afferents, which triggers itch.
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8could be involved in itch. It was pre-
viously hypothesized that the primary
pathway through which serotonin
causes itch is via stimulation of hista-
mine release from mast cells. However,
contrary to this idea, antihistamines
failed to reduce serotonin-induced
itch sensation in humans (Hosogi
et al., 2006). Thus, the mechanisms
of serotonin-induced itch remained
unknown.
A role for 5-HT7 and TRPA1 in
serotonin-mediated itch
A recent study has demonstrated that
one way in which serotonin induces
itch is via direct activation of 5-HT7
(encoded by HTR7), which is expressed
on subsets of primary sensory afferents
(Morita et al., 2015). In this study,
mice lacking either HTR7 or TRPA1
showed substantially reduced scratch-
ing behavior in response to an intrader-
mal injection of a 5-HT7-selective
agonist. Furthermore, HTR7 and TRPA1
knockout mice scratched considerably
less in a model of atopic dermatitis.Journal of Investigative Dermatology (2016), VolumHowever, it seemed likely that this was
only part of the serotonin-itch story,
because the 5-HT2-selective agonist,
a-methyl-5HT, is a potent pruritogen
in mice. Akiyama et al. (2016) provide
further insight into themolecular players
involved in serotonin-evoked itch by
defining a TRPV4-dependent pathway
that is likely to be downstream of 5-HT2-
mediated itch.
An unexpected role for TRPV4
in serotonin-mediated itch
The original goal of this study was to
investigate a possible role for TRPV4
in itch. TRPV4 is upregulated in the
skin of individuals with certain itch
conditions (Moore et al., 2013; Yang
et al., 2015), suggesting that it may be
involved in itch in humans. Interest-
ingly, TRPV4 knockout mice displayed
a significant reduction in scratching
behavior in response to serotonin, but
not to histamine, chloroquine, or
SLIGRL (Akiyama et al., 2016). A
TRPV4 antagonist also reduced sub-
stantially the amount of serotonin-e 136evoked scratching, supporting the idea
that TRPV4 is critical to serotonin
signaling in normal mice. Importantly,
the authors showed that the change in
response to serotonin in the TRPV4
knockout mice was specifically a
decrease in serotonin-evoked itch be-
haviors, and not a change in serotonin-
evoked pain behaviors. This study
demonstrates that TRPV4 is a key
downstream component of serotonin-
evoked itch (Figure 1).
To link serotonin to TRPV4 and the
activation of sensory neurons, the au-
thors visualized calcium responses to
serotonin in dorsal root ganglion neu-
rons. They found that approximately
90% of sensory neurons that respond to
serotonin also expressed TRPV4.
Serotonin-mediated activation was
dependent on TRPV4, as a TRPV4
antagonist reduced significantly the
calcium response to the application
of serotonin. In support of this finding,
the authors demonstrated that the pro-
portion of neurons that responded to
serotonin was reduced significantly in
TRPV4 knockout mice. Interestingly,
the proportion of neurons responding to
other types of pruritogens did not
change in mice lacking TRPV4, indi-
cating that TRPV4 plays an important
and specific role in responses to sero-
tonin in primary sensory neurons.
To identify the receptor through which
serotonin acts, Akiyama et al. (2016)
used subtype-specific antagonists for
5-HT1 and 5-HT2. The 5-HT2 antagonist,
but not the 5-HT1 antagonist, reduced
serotonin-evoked scratching. This
finding raises the possibility that 5-HT2,
acting via TRPV4, is a key mediator
of serotonin-evoked itch. Thus, there
appear to be at least two distinct path-
ways through which serotonin mediates
itch: a TRPA1-dependent pathway that
mediates 5-HT7-mediated itch, as well
as a TRPV4-dependent pathway that
likely mediates 5-HT2-mediated itch.
What remains to be tested is whether
these receptors are expressed on distinct
or overlapping populations of primary
sensory afferents.
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Melanoma: A Novel Co-Inhibitory
Pathway with Potential for
Clinical Intervention
Karsten Mahnke1 and Alexander H. Enk1Inozume et al. describe a novel immunosuppressive mechanism in melanoma
that is triggered by the interaction between CD155 (expressed by melanomas)
and T-cell Ig and ITIM domain (TIGIT) (expressed by tumor inﬁltrating lym-
phocytes). This pathway exists in addition to the “classical” co-inhibitory PD-1-
PD-L1 pathway. Hence, the combinatorial blockage of both pathways by speciﬁc
antibodies resulted in the greatly enhanced effector function of melanoma-
speciﬁc cytotoxic T cells. Given that CD155-TIGIT signaling exerts potent
inhibitory action in different subsets of immune cells and that CD155 is
expressed broadly in several tumor entities, this report points toward a novel
and promising therapeutic strategy to combine different checkpoint blocking
agents for greater success in antitumor therapy.
Journal of Investigative Dermatology (2016) 136, 9e11. doi:10.1016/j.jid.2015.10.048The inhibitory TIGIT-CD155
pathway
Immune responses are regulated by the
concerted action of immunostimulatory
and immunosuppressive signals that are
conveyed between antigen-presenting
cells and effector T cells. The balance
of this interplay is often tipped by
tumors toward a more immunosup-
pressive environment. Thereby, tumorsmay utilize receptors or ligands that
normally would trigger inhibitory
pathways in effector T cells. Several
receptors and/or ligands, such as PD-
L1, PD-1, CTLA-4, CD155, and TIGIT,
have been identified as important reg-
ulatory molecules. Among these the
most recently identified inhibitory pair
is T-cell Ig and ITIM domain (TIGIT) and
its ligand CD155 (Yu et al., 2009).ity Heidelberg, Heidelberg, Germany
Dermatology, Ruprecht-Karls-University
idelberg, Germany. E-mail: karsten.mahnke@The molecule TIGIT was identified
initially in a genome-wide screen for
molecules that (a) are expressed by im-
mune cells and (b) contain the well-
defined inhibitory ITIM motif, which is
known to mediate inactivating signals in
a variety of immune cells. TIGIT is
expressed normally by activated T cells,
regulatory T cells (Treg), and natural
killer (NK) cells. The poliovirus receptor
(CD155) and Nectin-2 (CD112) have
been identified as relevant ligands (Li
et al., 2014; Stanietsky et al., 2009; Yu
et al., 2009). TIGIT competes with the
molecules CD226 and CD96 for bind-
ing to CD155 and CD112, respectively,
but among all respective receptor-ligand
combinations, TIGIT exhibits the stron-
gest affinity for CD155. Interestingly, the
other known receptor for CD155,
CD226, conveys activating signals into
T cells, whereas TIGIT clearly has sup-
pressive activity. This competition of an
inhibitory receptor (TIGIT) and a stim-
ulatory receptor (CD226) for one ligand
(CD155) is reminiscent of the CTLA4-
CD28-B7 axis. This similarity of the
CD155-TIGIT interaction to the already
known suppressive CTLA4-CD28
pathway, as well as the expression of
TIGIT by exhausted T cells and by Treg,
prompted investigators to speculate that
the TIGIT-CD155 axis in tumors might
serve as a checkpoint for tumor growth
(Chauvin et al., 2015; Johnston et al.,
2015; Li et al., 2014).
Inozume et al. (2016) report that
melanoma cell lines, as well as mela-
noma tissue samples, express CD155
strongly. In functional assays, the au-
thors show that the effector functions
are suppressed completely in tumor-
specific T cells that express the corre-
sponding inhibitory receptor TIGIT.
But antibody-mediated blockade of
CD155 could, at least partially, reverse
these effects, leading to increased
antitumor activity by cytotoxic T cells
against the melanoma cells. Interest-
ingly, simultaneous blockade of the
previously identified checkpoint mole-
cule PD-L1 had an additive effect, with
anti-PD-L1 and anti-CD155 antibodies
together restoring the effector func-
tion of tumor infiltrating lymphocytes
almost completely. Thus, in addition
to the already defined PD-L1-PD-1 axis
in melanomas, a second inhibitory
pathway, characterized by CD155-
TIGIT interplay, is active.www.jidonline.org 9
